B7-H5 Overview
Molecule Name
V-domain Ig suppressor of T-cell activation
Synonyms
B7-H5,SISP1,Gi24,VISTA
Drug Development Progress
Drugs in Clinical Trials8
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
Dies1，VSIR，V-Set Domain-Containing Immunoregulatory Receptor，DD1alpha，B7-H5，PD-1H，B7H5，GI24，Stress-induced secreted protein-1，PP2135，SISP1，UNQ730/PRO1412，V-type immunoglobulin domain-containing suppressor of T-cell activation，V-Set Immunoregulatory Receptor，V-Domain Ig Suppressor Of T Cell Activation，PDCD1 Homolog，C10orf54，Sisp-1，VISTA，Chromosome 10 Open Reading Frame 54，Stress Induced Secreted Protein 1，Platelet Receptor Gi24，Death Domain1alpha
Background
Platelet receptor Gi24, also known as B7-H5 and stress-induced secreted protein-1 (Sisp-1), is a protein that in humans is encoded by the C10orf54 gene, which contains 1 Ig-like (immunoglobulin-like) domain. As for C10orf54 gene, C10orf54 appears to positively interact with BMP-4, potentiating BMP signaling and the transition from an undifferentiated to a differentiated state on ESCs. Human C10orf54 undergoes proteolytic cleavage by MT1-MMP, generating a soluble 30 kDa extracellular fragment plus a 25-30 kDa membrane-bound fragment.
B7-H5 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Solnerstotug | SNS-101; SNS-VISTA | Phase 2 Clinical | Sensei Biotherapeutics Inc | Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Trovostobart | KVA-12123; KVA-12.1 | Phase 2 Clinical | GigaGen Inc | Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Uterine Neoplasms | Details |
| Onvatilimab | CI-8993; JNJ-61610588 | Phase 1 Clinical | Immunext Inc, Johnson & Johnson Innovative Medicine | Neoplasms; Solid tumours | Details |
| HMBD-002 | HMBD-002 | Phase 1 Clinical | Hummingbird Bioscience | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| PMC-309 | PMC-309 | Phase 1 Clinical | Pharmabcine | Neoplasms; Solid tumours | Details |
| TBS-2025 | TBS-2025 | Phase 1 Clinical | Kintara Therapeutics Inc | Leukemia, Myeloid, Acute | Details |
| LFD-200 | LFD-200 | Phase 1 Clinical | Lifordi Immunotherapeutics Inc | Arthritis, Rheumatoid | Details |